PULM Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Pulmatrix Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerPULM

Market Cap5.0M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

Pulmatrix Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for PUR0200 in Chronic Obstructive Pulmonary Disease (COPD) (Phase 1).

Pipeline

Asset	Indication	Modality	Stage	Public Note
PUR0200	Chronic Obstructive Pulmonary Disease (COPD)	n/a	Phase 1	Public pipeline row
RUT058-60	Postoperative Wound Infection-deep \| Post Operative Wound Infection	n/a	Phase 1 \| Phase 2	Public pipeline row
PUR003	Asthma \| Lung Diseases \| Bronchial Diseases	n/a	Phase 1	Public pipeline row
PUR118	Cystic Fibrosis	n/a	Phase 1	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01096173	n/a	COMPLETED	10	2010-06
NCT00989521	Phase 1	COMPLETED	7	2011-10
NCT01543191	Phase 1	COMPLETED	10	2012-12
NCT01921712	Phase 1	COMPLETED	38	2013-12
NCT02280395	Phase 1 \| Phase 2	TERMINATED	9	2015-06

Scientific Context

literature_publication | Interferon-gamma Production Defects Characterize Immune Responses in Patients With Chronic Pulmonary Aspergillosis.
literature_publication | COPD exacerbations: Major events in the course of the disease.
literature_publication | Influenza-associated invasive aspergillosis in the ICU: a prospective, multicentre cohort study.
literature_publication | Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
literature_publication | Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report.

Want the full PULM research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.